New US lawsuit over insulin prices will have minimal impact on Novo Nordisk, says analyst
A California lawsuit could potentially move the needle slightly in early Friday trading, says an analyst, but will likely be added to the pile of other legal cases of non-material impact.
by marketwire, translated by daniel pedersen
Another lawsuit has hit Novo Nordisk and its rivals in the US, Eli Lilly and Sanofi, as the state of California has leveled accusations against the insulin industry for overpricing products.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
